. 2014 Jan 15;10(4):986–994. doi: 10.4161/hv.27682

Table 1. Prevalence of cervical HPV infection and associations between infection and selected characteristics in the univariate and multivariate analyses.

				HPV prevalence			Univariate model		Multivariate Model 1		Multivariate Model 2
Factor	HPV pos/N tested	Fisher exact test (P)	χ2 for trend	Rate (%)	95%CI		OR	95%CI	OR	95%CI	OR	95%CI
Age group
13–15	3/79	<0.0001		3.80	-0.42-8.01	1		ref	1	ref	1	ref
16–18	14/285			4.91	2.40–7.42	1.31		0.37–4.67	1.01	0.28–3.78	1.93	0.40–9.38
19–21	25/120			20.83	13.57–28.10	6.67		1.94–22.93	4.13	1.17–14.60	9.61	1.71–54.09
22–26	44/312			14.10	10.24-17.96	4.16		1.26–13.77	2.33	0.68–7.99	6.25	1.03–37.79
Geographical origin
Italian	77/752	0.044		10.24	8.07–12.41	1		ref	1	ref	1	ref
Foreign born	9/44	0.044		20.45	8.54–32.37	2.25		1.04–4.87	1.70	0.79–3.67	1.79	0.81–3.96
Cigarette smoking
yes	40/292	0.05		13.70	9.75–17.74	1.58		1.0–2.48	1.29	0.80–2.10	1.29	0.78–2.13
never	46/504	0.05		9.13	6.61–11.64	1		ref	1	ref	1	ref
HPV vaccine
No	71/663	0.88		10.71	8.36–13.06	0.94		0.52–1.7	1.13	0.61–2.08	1.13	0.60–2.12
Yes	15/133	0.88		11.28	5.90–16.65	1		ref	1	ref	1	ref
Age of 1^st sexual intercourse
≤15	27/278	0.40		9.71	6.23–13.19	0.8		0.49–1.3	1.10	0.61–1.97	1.23	0.63–2.40
>15	57/481	0.40		11.85	8.96–14.74	1		ref	1	ref	1	ref
Δ years
0	5/104	0.0012	<0.0001	4.81	0.70–8.92	1		ref	1	ref	1	ref
1	8/151			5.30	1.73–8.87	1.11		0.35–3.49	0.56	0.16–1.93	0.56	0.16–1.93
2	7/91			7.69	2.22–13.17	1.65		0.50–5.39	0.52	0.14–2.02	0.52	0.14–2.02
3	7/65			10.77	3.23–18.31	2.39		0.72–7.88	0.37	0.08–1.65	0.37	0.08–1.65
4	10/67			14.93	6.39–23.46	3.47		1.13–10.67	0.33	0.07–1.56	0.33	0.07–1.56
5	9/65			13.85	5.45–22.24	3.3		1.05–10.35	0.30	0.06–1.45	0.30	0.06–1.45
6	13/51			25.49	13.53–37.45	6.77		2.26–20.30	0.62	0.13–2.97	0.62	0.13–2.97
7	8/52			15.38	5.58–25.19	3.6		1.11–11.63	0.33	0.06–1.80	0.33	0.06–1.80
≥8	17/111			15.32	8.62–22.02	3.58		1.27–10.10	0.33	0.07–1.67	0.33	0.07–1.67
Total N of sexual partners
1	14/326	<0.0001	<0.0001	4.29	2.09–6.50	1		ref	1	ref	1	ref
2 -5	54/390			13.85	10.42–17.27	3.58		1.95–6.58	2.69	1.42–5.09	3.69	1.71–8.00
>5	17/70			24.29	14.24–34.33	7.15		3.33–15.36	4.71	2.10–10.57	6.44	2.46–16.86
N of sexual partners (last 6 mo)
0	7/57	0.015	0.06	12.28	3.76–20.80	1.33		0.58–3.06	2.09	0.86–5.09	2.89	1.13–7.42
1	61/640			9.53	7.26–11.81	1		ref	1	ref	1	ref
>1	17/86			19.77	11.35–28.18	2.34		1.29–4.23	1.89	0.92–3.91	2.07	0.97–4.40
Current use of EP
Yes	31/283	0.59		10.95	7.32–14.59	1.18		0.70–1.98	0.78	0.45–1.35	0.76	0.43–1.35
No	33/350	0.59		9.43	6.37–12.49	1		ref	1	ref	1	ref
Past use of EP
Yes	42/266	0.0003		15.79	11.41–20.17	2.62		1.53–4.49	1.35	0.71–2.59	1.61	0.79–3.29
No	23/345	0.0003		6.67	4.03–9.3	1		ref	1	ref	1	ref
Ever use of EP
Yes	51/407	0.023		12.54	9.31–15.75	2.5		1.1–5.65	1.00	0.41–2.44	1.49	0.54–4.01
No	7/129	0.023		5.43	1.52–9.34	1		ref	1	ref	1	ref
Pregnancies
Yes	5/34	0.40		14.71	2.8–26.61	1.45		0.54–3.85	0.75	0.27–2.07	0.69	0.25–1.93
No	81/762	0.40		10.63	8.44–12.82	1		ref	1	ref	1	ref
History of STIs or genital infections*
Yes	33/152	<0.0001		21.71	15.16–28.26	3.08		1.91–4.96	1.85	1.09–3.15	1.86	1.07–3.24
No	53/641	<0.0001		8.27	6.14–10.40	1		ref	1	ref	1	ref

Model 1 is adjusted for age and lifetime sexual partners. Model 2 is adjusted for age, lifetime sexual partners, and time between first sexual intercourse and enrollment (Δ years). °Δ years, years between first sexual intercourse and enrollment in the study. *STIs or genital infections reported in the history: 115 genital mycosis, 25 genital warts, 20 bacterial vaginosis, 8 genital HSV, 6 Chlamydia, 2 Trichomoniasis. In bold are the statistically significant results.